logo
logo

Angelini Ventures invests in a $39 million Series A extension round for Therini Bio, advancing treatments for neurodegenerative diseases. This round brings total funding to $75 million.

May 14, 2025•3 months ago

Amount Raised

$39 Million

Round Type

series a

SacramentoBiotechnology

Investors

Sanofi VenturesMrl Ventures FundFoundation For A Better WorldEli Lilly And CompanyDolby Family VenturesDementia Discovery FundSv Health Investors' Biotech FundApollo Health VenturesAngelini Ventures

Description

Angelini Ventures participates in a $39 million extension of Therini Bio's Series A financing round, aimed at developing fibrin-targeting immunotherapies for neurodegenerative diseases. The investment will fund Phase 1b studies for the lead candidate, THN391, targeting Alzheimer's Disease and Diabetic Macular Edema. The total raised in this Series A round now stands at $75 million, with participation from top-tier investors including Apollo Health Ventures and SV Health Investors.

Company Information

Company

Therini Bio

Location

Sacramento, California, United States

About

Therini Bio, Inc. is a biotechnology company dedicated to the research and development of novel therapeutics for the treatment of neuroinflammatory diseases due to vascular dysfunction. Our approach will be generally applicable across a range of inflammatory diseases including peripheral indications. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

FundzWatch™ Score

78
Medium Activity

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech